SecBot SecBot
6-K ·Filed Apr 13, 2026

NONOF

NOVO NORDISK A S
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago SEC0001171843-26-002394
Notable filing: 6-K
Actionable Insight • Neutral

The share repurchase signals management's confidence in the company's long-term prospects and provides near-term support for the stock price. Investors should monitor the pace of future repurchases and whether the company maintains this capital return strategy alongside its R&D investments.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
NONOF ▲ +30.91% at T+60d
NEUTRAL call +30.91% · α vs SPY +21.99% · entry $38.08 → $49.85
Entry = T+0 close
Apr 13, 2026
via day close
T+1d
+1.94%
call +1.94% · α +0.73%
$38.82
settled 7mo ago
T+5d
+4.28%
call +4.28% · α +0.98%
$39.71
settled 6mo ago
T+20d
+21.24%
call +21.24% · α +13.52%
$46.17
settled 6mo ago
T+60d
+30.91%
call +30.91% · α +21.99%
$49.85
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Novo Nordisk announced a share repurchase program, buying back B shares worth DKK 2.835 billion ($383 million) from February to April 2026. This is part of a larger DKK 15 billion ($2.03 billion) share buyback program aimed at returning capital to shareholders.

Key Facts

  • Novo Nordisk repurchased 11,007,992 B shares for DKK 2.835 billion ($383 million) between February 4 and April 10, 2026
  • This is part of a larger DKK 15 billion ($2.03 billion) share repurchase program over 12 months
  • The company now holds 28,397,791 B shares (0.6% of share capital) as treasury shares
  • The repurchase program is being executed under EU safe harbor rules

Financial Impact

DKK 2.835 billion ($383 million) in share repurchases completed, with up to DKK 15 billion ($2.03 billion) planned over 12 months

cashdilution

Risk Factors

  • Large cash outflow could impact R&D investments or dividend payments
  • Repurchase program may be scaled back if business conditions deteriorate

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-002394
Document: 0001171843-26-002394-index-headers.html0001171843-26-002394
Document: 0001171843-26-002394-index.html0001171843-26-002394
Document: 0001171843-26-002394.txt0001171843-26-002394
6 reports for NONOF
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for NONOF — sortable, filterable
TypeNow
Jun 8, 2026
20w ago
6-K
NEUTRAL ★ 3/10
$41.25 $46.09▲ +11.73%▲ +8.42%$38.98 (−5.50%)
May 27, 2026
21w ago
6-K
NEUTRAL ★ 3/10
$44.80 $46.30▲ +3.35%▲ +1.47%$38.98 (−12.99%)
May 22, 2026
22w ago
6-K
BULLISH ★ 7/10
$43.80 $44.78▲ +2.24%▼ −0.95%$38.98 (−11.00%)
Apr 13, 2026
28w ago
6-K
NEUTRAL ★ 4/10
$38.08 $49.85▲ +30.91%▲ +21.99%$38.98 (+2.36%)
Apr 7, 2026
29w ago
6-K
NEUTRAL ★ 3/10
$35.92 $50.00▲ +39.20%▲ +25.93%$38.98 (+8.52%)
Mar 27, 2026
30w ago
6-K
NEUTRAL ★ 2/10
$35.29 $46.84▲ +32.73%▲ +16.66%$38.98 (+10.46%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 9h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026